4.2 Editorial Material

New renal anemia drugs: is there really anything new on the horizon?

期刊

EXPERT OPINION ON EMERGING DRUGS
卷 19, 期 1, 页码 1-4

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2014.872239

关键词

chronic kidney disease; dialysis; erythropoietin; peginesatide; renal anemia

向作者/读者索取更多资源

Anemia has remained one of the most characteristic and visible manifestations of chronic renal failure for over 150 years. The pathogenesis of anemia of chronic kidney disease (CKD) is multifactorial with inadequate production of erythropoietin being the leading factor. The development of recombinant human erythropoietin (epoetin) in the late 1980s was a milestone in treatment of renal anemia. Despite new drugs, our 'good old friend' erythropoietin-stimulating agents are our everyday life in nephrology practice. It seems that peginesatide would not become a new approach for treating anemia of CKD patients, but rather a falling star. Several new strategies for treating the anemia of CKD are currently being investigated in clinical trials, including prolyl hydroxylase inhibitors and modulators of hepcidin activity, but their role in the management of this condition remains to be established. As shown by the expert in this review, we have to take into account not only the safety and convenience of administration but also cost-effectiveness, while bio-similars are consequently knocking at the doors of dialysis units more and more, particularly in Europe.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据